A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer

[1] Fitzmaurice C(2015)The global burden of cancer 2013 JAMA Oncol 1 505-527

[2] Dicker D(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[3] Pain A(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697

[4] Hamavid H(2021)Japanese gastric cancer treatment guidelines 2018 (5th edition) Gastric Cancer 24 1-21

[5] Moradi-Lakeh M(2016)Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Gastric Cancer 19 329-338

[6] Fitzmaurice C(2018)Surgery with curative intent for stage IV gastric cancer: is it a reality of illusion? Ann Gastroenterol Surg 2 339-347

[7] Allen C(2020)Clinical significance of conversion surgery for gastric cancer with peritoneal dissemination: a retrospective study Oncology 98 798-806

[8] Barber RM(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247

[9] Barregard L(2011)Japanese classification of gastric carcinoma: 3rd English edition Gastric Cancer 14 101-112

[10] Bhutta ZA(2005)Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273-278

[1] Fitzmaurice C(2015)The global burden of cancer 2013 JAMA Oncol 1 505-527

[2] Dicker D(2017)Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study JAMA Oncol 3 524-548

[3] Pain A(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697

[4] Hamavid H(2021)Japanese gastric cancer treatment guidelines 2018 (5th edition) Gastric Cancer 24 1-21

[5] Moradi-Lakeh M(2016)Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification Gastric Cancer 19 329-338

[6] Fitzmaurice C(2018)Surgery with curative intent for stage IV gastric cancer: is it a reality of illusion? Ann Gastroenterol Surg 2 339-347

[7] Allen C(2020)Clinical significance of conversion surgery for gastric cancer with peritoneal dissemination: a retrospective study Oncology 98 798-806

[8] Barber RM(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247

[9] Barregard L(2011)Japanese classification of gastric carcinoma: 3rd English edition Gastric Cancer 14 101-112

[10] Bhutta ZA(2005)Amplification of HER-2 in gastric carcinoma: association with topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab Ann Oncol 16 273-278